

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 September 2025 (11.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/188901 A9



(51) International Patent Classification:

A61K 38/47 (2006.01) A61K 9/00 (2006.01)
A61K 47/68 (2017.01) A61K 31/4985 (2006.01)

(21) International Application Number:

PCT/US2025/018582

(22) International Filing Date:

05 March 2025 (05.03.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/561,701 05 March 2024 (05.03.2024) US
63/673,280 19 July 2024 (19.07.2024) US

(71) Applicant: **HALOZYME, INC.** [US/US]; 12390 El Camino Real, San Diego, CA 92130 (US).

(72) Inventors: **CONNOR, Robert**; c/o Halozyme, Inc., 12390 El Camino Real, San Diego, CA 92130 (US). **KANG, David**; c/o Halozyme, Inc., 12390 El Camino Real, San Diego, CA 92130 (US). **NEKOROSKI, Tara**; c/o Halozyme, Inc., 12390 El Camino Real, San Diego, CA 92130 (US). **LABARRE, Michael**; c/o Halozyme, Inc., 12390 El Camino Real, San Diego, CA 92130 (US).


(74) Agent: **DUNLAP, Andrew L.** et al.; Haynes Beffel & Wolfeld LLP, P.O. Box 366, 60 Stone Pine Road, Suite 200, Half Moon Bay, CA 94019 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES

FIG. 1



(57) Abstract: Provided are combination dosing regimens comprising administering an antibody-drug conjugate and hyaluronidase. Combinations and compositions containing the antibody-drug conjugate and hyaluronidase are provided. The dosing regimens and combinations are for treating or preventing cancer.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:

26 February 2026 (26.02.2026)

(15) Information about Correction:

see Notice of 26 February 2026 (26.02.2026)

Previous Correction:

see Notice of 02 October 2025 (02.10.2025)